[Toronto, May 21, 2025] – Geneseeq Technology Inc., shared today that 12 research studies have been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, underscoring the company’s continued innovation in cell-free DNA (cfDNA)–based early detection, diagnosis, and minimal residual disease (MRD) monitoring.
The studies span multiple tumor types—including pancreatic, biliary, renal, gastric, lung, ovarian, and esophageal cancers—and collectively demonstrate the power of Geneseeq’s multi-omics platform, integrating whole-genome sequencing, fragmentomics, and AI-driven modeling for non-invasive cancer detection. In addition, SCENT-2 trial study, which was selected for oral presentation (Abstract #7006), evaluated the combination of sintilimab and chidamide followed by P-GemOx in treatment-naïve ENKTL patients using Geneseeq Hemasalus™ panel.
All studies were conducted in collaboration with leading cancer centers and reflect Geneseeq’s mission to transform oncology through integrated genomics and AI-powered innovation.
Featured Presentations at ASCO 2025:
|
Abstract ID |
Type |
Title |
|
7006 |
Oral |
|
|
3044 |
Poster |
|
|
3047 |
Poster |
Accurate differentiation of malignant and benign gastric lesions using cell-free DNA biomarkers. |
|
4131 |
Poster |
Integration of cfDNA fragmentomics for early biliary tract cancer detection. |
|
4191 |
Poster |
|
|
4534 |
Poster |
Early detection of renal cell carcinoma: A novel cfDNA fragmentomics-based liquid biopsy assay. |
|
8559 |
Poster |
|
|
5548 |
Poster |
|
|
e16287 |
Online |
|
|
e15063 |
Online |
|
|
e20046 |
Online |
Distinct margin mutation dissemination patterns in EGFR L858R-mutated lung cancers |
|
e15064 |
Online |
About Geneseeq:
Geneseeq Technology Inc. (Geneseeq) is a research-driven leader in precision oncology, utilizing cutting-edge next-generation sequencing (NGS) technologies to advance cancer care. The company provides comprehensive genomic profiling solutions for all tumor types, including pan-cancer and cancer-specific panels, alongside cutting-edge tools for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Geneseeq has reached key regulatory milestones to date, including CE-IVD certification for its solid tumor and hematologic cancer panels, and FDA Breakthrough Device Designation for its MCED test, CanScan®. The company has also received approval from the National Medical Products Administration (NMPA) for GeneseeqPrime™, designed for tumor mutational burden (TMB) detection in lung cancer.
